Key result
Structure-based drug design targeting the RNA-dependent RNA polymerase has yielded successful antivirals for HCV and SARS-CoV-2, but progress in Flaviviruses is hampered by a lack of structural data.
Why the study?
RdRp is an essential enzyme for viral replication and an optimal target for antiviral drug development, but the lack of structural details on catalytically-competent or ligand-bound RdRp can hamper structure-based drug design.
Structure-based drug design targeting RdRp has been successful for HCV and SARS-CoV-2, but is hindered in Flaviviruses due to a lack of detailed structural information.
Answers are grounded in this paper and cite their sources.
RdRp targeting may guide antivirals in virus-related cardiac injury; leaves open specific cardiovascular applications.
The RNA-dependent RNA polymerase (RdRp) is an essential enzyme for the viral replication process, catalyzing the viral RNA synthesis using a metal ion-dependent mechanism. In recent years, RdRp has emerged as an optimal target for the development of antiviral drugs, as demonstrated by recent approvals of sofosbuvir and remdesivir against Hepatitis C virus (HCV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), respectively. In this work, we overview the main sequence and structural features of the RdRp of emerging RNA viruses such as Coronaviruses, Flaviviruses, and HCV, as well as inhibition strategies implemented so far. While analyzing the structural information available on the RdRp of emerging RNA viruses, we provide examples of success stories such as for HCV and SARS-CoV-2. In contrast, Flaviviruses' story has raised attention about how the lack of structural details on catalytically-competent or ligand-bound RdRp strongly hampers the application of structure-based drug design, either in repurposing and conventional approaches.
No takes yet. Share an insight, caveat, or question.
Picarazzi et al. (2020) conducted a review in Emerging RNA viruses (Coronaviruses, Flaviviruses, HCV). Structure-based drug design targeting RdRp was evaluated. Structure-based drug design targeting the RNA-dependent RNA polymerase has yielded successful antivirals for HCV and SARS-CoV-2, but progress in Flaviviruses is hampered by a lack of structural data.
Synapse has enriched 10 related papers. Consider them for comparative context: